Evaluation of the Effect of Empagliflozin on Blood Pressure in Diabetic Patients with Chronic Kidney Disease

The Effect of Empagliflozin on Blood Pressure in Diabetic Patients with Chronic Kidney Disease: A Double-Blind Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250717066530N1

Enrollment

Registered

2025-07-26

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chronic Kidney Disease. Condition 2: Diabetic Mellitus Type II. Chronic kidney disease (CKD) Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Patients will receive empagliflozin at a dose of 10 mg daily for a duration of 12 weeks. Intervention 2: Control group: Patients in the placebo group will receive a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with CKD defined by the standard criterion of eGFR between 20–60 mL/min/1.73 m² at the initial visit Consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients with polycystic kidney disease and patients undergoing kidney transplantation Use of thiazide diuretics and ARBs

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure. Timepoint: At baseline, 6 weeks, and 12 weeks following study initiation. Method of measurement: Systolic blood pressure will be assessed using 24-hour ambulatory blood pressure monitoring (ABPM).;Diastolic blood pressure. Timepoint: At baseline, 6 weeks, and 12 weeks following study initiation. Method of measurement: Diastolic blood pressure will be assessed using 24-hour ambulatory blood pressure monitoring (ABPM).	—

Measure

Time frame

Systolic blood pressure. Timepoint: At baseline, 6 weeks, and 12 weeks following study initiation. Method of measurement: Systolic blood pressure will be assessed using 24-hour ambulatory blood pressure monitoring (ABPM).;Diastolic blood pressure. Timepoint: At baseline, 6 weeks, and 12 weeks following study initiation. Method of measurement: Diastolic blood pressure will be assessed using 24-hour ambulatory blood pressure monitoring (ABPM).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVida Veisi Bigzadi

Zahedan University of Medical Sciences

veisivida0@gmail.com+98 54 3341 0707

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026